StreetInsider.com News Articles

Form SCHEDULE 13G/A Rein Therapeutics, Inc. Filed by: Voss Capital, LP

Tue, 14 Jul 2026 19:23:00 -0400

si-local-file:///var/storage/secattach/20260714/26769385.html

Form SCHEDULE 13G/A Rein Therapeutics, Inc. Filed by: Voss Capital, LP

Tue, 14 Jul 2026 19:23:00 -0400

si-local-file:///var/storage/secattach/20260714/26769385.html

Rein Therapeutics expands Phase 2 trial to UK, enrolls 16 patients

Thu, 11 Jun 2026 08:02:13 -0400

Rein Therapeutics Inc. (NASDAQ: RNTX) announced the first patient has been randomized in the United Kingdom as part of its Phase 2 RENEW clinical trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis.

The company has enrolled 16 patients to date in the trial. Clinical trial sites are currently enrolling patients in the United States, Australia, and the United Kingdom. Additional sites in two more countries are expected to begin enrollment in the coming months.

"We are pleased to see continued enrollment momentum in our trial and the activation of additional international sites," said Brian Windsor, Chief Executive Officer of Rein Therapeutics.

Rein Therapeutics expands Phase 2 trial to UK, enrolls 16 patients

Thu, 11 Jun 2026 08:02:13 -0400

"We are pleased to see continued enrollment momentum in our trial and the activation of additional international sites," said Brian Windsor, Chief Executive Officer of Rein Therapeutics.

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Thu, 11 Jun 2026 08:00:00 -0400

16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF)
First patient randomized in the United Kingdom
Clinical trial sites now actively enrolling in the United States, Australia, and the United Kingdom
Two additional countries expected to be added in the coming months

AUSTIN, Texas, June 11, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2 RENEW clinical

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Thu, 11 Jun 2026 08:00:00 -0400

16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF)
First patient randomized in the United Kingdom
Clinical trial sites now actively enrolling in the United States, Australia, and the United Kingdom
Two additional countries expected to be added in the coming months

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Thu, 11 Jun 2026 08:00:00 -0400

16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF)
First patient randomized in the United Kingdom
Clinical trial sites now actively enrolling in the United States, Australia, and the United Kingdom
Two additional countries expected to be added in the coming months

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Thu, 11 Jun 2026 08:00:00 -0400

16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF)
First patient randomized in the United Kingdom
Clinical trial sites now actively enrolling in the United States, Australia, and the United Kingdom
Two additional countries expected to be added in the coming months

Form DEFA14A Rein Therapeutics, Inc.

Mon, 08 Jun 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260608/26615220.html

Form DEFA14A Rein Therapeutics, Inc.

Mon, 08 Jun 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260608/26615220.html

Form ARS Rein Therapeutics, Inc. For: Dec 31

Mon, 08 Jun 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260608/26615221.html

Form ARS Rein Therapeutics, Inc. For: Dec 31

Mon, 08 Jun 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260608/26615221.html

Form DEF 14A Rein Therapeutics, Inc. For: Jul 20

Mon, 08 Jun 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260608/26615219.html

Form DEF 14A Rein Therapeutics, Inc. For: Jul 20

Mon, 08 Jun 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260608/26615219.html

Rein Therapeutics (RNTX) PT Lowered to $8 at H.C. Wainwright

Mon, 01 Jun 2026 06:55:38 -0400

(Updated - June 1, 2026 6:55 AM EDT)

H.C. Wainwright analyst Brandon Folkes lowered the price target on Rein Therapeutics (NASDAQ: RNTX) to $8.00 (from $10.00) while maintaining a Buy rating.

The analyst commented: "RNTX reported a meaningful set of 1Q26 updates, with the most important development being the post-quarter $57.5M common-stock financing, which we believe materially changes the stock setup by removing the largest overhang on the story and funding the ongoing RENEW Phase 2 trial of LTI-03 in IPF through completion. The regulatory overhang had already largely cleared with the FDA allowing the Phase 2 program to resume and the

Rein Therapeutics (RNTX) PT Lowered to $8 at H.C. Wainwright

Mon, 01 Jun 2026 06:55:38 -0400

(Updated - June 1, 2026 6:55 AM EDT)

H.C. Wainwright analyst Brandon Folkes lowered the price target on Rein Therapeutics (NASDAQ: RNTX) to $8.00 (from $10.00) while maintaining a Buy rating.

Form 4 Rein Therapeutics, Inc. For: May 21 Filed by: VON RICKENBACH JOSEF H

Thu, 28 May 2026 20:16:00 -0400

si-local-file:///var/storage/secattach/20260528/26569382.html

Form 4 Rein Therapeutics, Inc. For: May 21 Filed by: VON RICKENBACH JOSEF H

Thu, 28 May 2026 20:16:00 -0400

si-local-file:///var/storage/secattach/20260528/26569382.html

Form PRE 14A Rein Therapeutics, Inc. For: Jul 20

Thu, 28 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260528/26568421.html

Form PRE 14A Rein Therapeutics, Inc. For: Jul 20

Thu, 28 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260528/26568421.html

Rein Therapeutics closes $57.5 million stock offering

Mon, 18 May 2026 08:01:09 -0400

Rein Therapeutics Inc. (NASDAQ: RNTX) completed its underwritten public offering of common stock, raising $57.5 million in gross proceeds before fees and expenses, according to a company statement.

The clinical-stage biopharmaceutical company sold 57.5 million shares at $1.00 per share. The transaction included the full exercise of underwriters' over-allotment option to purchase an additional 7.5 million shares.

The offering consisted solely of common stock with no warrants or derivative securities issued. Investors included Adar1 Capital Management LLC, Ikarian Capital LLC, Bios Partners, Stonepine Capital Management, Cable Car Capital LP, and Second Line Capital.

Rein plans to use proceeds to fund its Phase 2

Rein Therapeutics closes $57.5 million stock offering

Mon, 18 May 2026 08:01:09 -0400

Rein Therapeutics Inc. (NASDAQ: RNTX) completed its underwritten public offering of common stock, raising $57.5 million in gross proceeds before fees and expenses, according to a company statement.

Rein plans to use proceeds to fund its Phase 2

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Mon, 18 May 2026 08:00:00 -0400

Total gross proceeds increased to $57.5 million
Offering consisted solely of common stock
Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028

AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten public offering of common stock, including the full exercise of the underwriters’ over-allotment option. The financing included new and existing healthcare-focused investors, including Adar1

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Mon, 18 May 2026 08:00:00 -0400

Total gross proceeds increased to $57.5 million
Offering consisted solely of common stock
Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Mon, 18 May 2026 08:00:00 -0400

Total gross proceeds increased to $57.5 million
Offering consisted solely of common stock
Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028